Company intelligence / Profile preview

Gamma Medica

Salem, New Hampshire, United Statescmr-naviscan.com ↗

Ownership: Private
Development stage: Commercial

Overview

Gamma Medica commercializes the FDA-approved LumaGEM Molecular Breast Imaging system, which provides high-sensitivity and specificity for early breast cancer detection in women with dense breasts. The product has been adopted by leading hospitals and centers across the U.S., received multiple industry awards, and has demonstrated clinical performance comparable to MRI at lower cost. The company also markets pre-clinical imaging systems for research use.

Therapeutic areas: Oncology
Modalities: Device
Industry: Medical Imaging

Partnerships

Alpha Imaging (distribution partner in Midwest/Mid Atlantic US)Hospital Services Limited/HSL (distribution partner UK/Ireland/Channel Islands)GE Healthcare/SII NanoTechnology for preclinical products distribution historically

Beyond the preview

Go deeper on Gamma Medica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma Medica.

Explore the full profile